DEC 30, 2016 2:11 PM PST

New Findings Drive Home Cancer's Vast Genetic Diversity

WRITTEN BY: Xuan Pham

A common misconception is that cancer is caused by a single mutation in the genetic code. In many cases, however, the single mutation is just the beginning of a cascade of genetic changes that snowball out of control. The complexity of these changes are highlighted in the most recent study of cancer, showing that just one type of cancer contains over 2,000 different variations alone.

Image credit: Pixabay.com

"A tumor is not a single disease," said Dechen Lin, assistant professor and research scientist in the Division of Hematology and Oncology in the Cedars-Sinai Department of Medicine, and the study’s co-author. "It's many diseases within the same person and over time. There are millions of cells in a tumor, and a significant proportion of them are different from each other."

In particular, cancer has been described as a process of clonal expansion by Bert Vogelstein, a leading cancer geneticist from Johns Hopkins. Essentially, mutations begets more mutations as cancer continues to divide and proliferate. So, by the time the cancer becomes advanced, the original mutation is now just one in a sea of other mutations.

But while cancer biologists new cells from a single tumor sample could be wildly different, they didn’t know the degree to which the differences can occur.

To study cancer’s heterogeneity, researchers from the Cedars-Sinai Medical Center focused on esophageal squamous cell carcinoma - cancer that occurs along the pipe that connects the throat and the stomach. With 51 samples from 13 patients, the team catalogued the variety of mutations that they found. They included mutations at the DNA level, as well as mutations at the epigenetic level.

In total, the team found a whopping 2,178 different genetic variations. This number is staggering considering the small number of patients and samples sizes that they started with. The vast number of changes underscores the deep complexities within cancer that we are only beginning to unravel.

"This study is on the leading edge of looking within a tumor for heterogeneity, or variations, across patients and within the same patient. It also is one of the very first studies to look at epigenetic changes from different areas within a single tumor in a global way," said Benjamin Berman, the study's co-senior author.

Considering the vast genetic diversity within the tumor and within any person, it’s a wonder that any drug works as expected. But in the case of treating cancer, the complexities of a single cancer type can explain why so many drugs do fail. In particular, drugs that target a particular pathway or mutation can very easily be thwarted by the thousands of other mutations at play within a cancer environment.

"Evidence suggests that tumor heterogeneity is one of the major causes of drug resistance and treatment failure in cancer," said H. Phillip Koeffler, professor of Medicine and the Mark Goodson Chair in Oncology Research at Cedars-Sinai, and the study’s co-senior author. "In light of this situation, deciphering the genomic diversity and evolution of tumors can provide a basis for identifying new targets and designing personalized medicine strategies."

Additional source: Cedars-Sinai Medical Center.

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 11, 2020
Cancer
Taking cancer treatment from a whole new angle
SEP 11, 2020
Taking cancer treatment from a whole new angle
New cancer research is looking at treatment for the disease from an entirely new angle: structurally. While chemotherapy ...
SEP 15, 2020
Cancer
Soy helps post-op treatment of bone cancer
SEP 15, 2020
Soy helps post-op treatment of bone cancer
New research published in the journal Acta Biomaterialia highlights the post-operative benefits of soy in treatment ...
SEP 25, 2020
Clinical & Molecular DX
Ray of Hope: Rare Cancer Biomarker Discovered
SEP 25, 2020
Ray of Hope: Rare Cancer Biomarker Discovered
Biliary tract cancer, or BTC, isn’t as talked about as breast or prostate cancers, probably because its incidence ...
OCT 05, 2020
Health & Medicine
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
OCT 05, 2020
Cannabis Chemotherapy Trial Shows Encouraging Phase II Results
Even with the best anti-nausea medications one in three patients receiving chemotherapy experiences vomiting, and about ...
OCT 14, 2020
Cancer
Research suggests statins could reduce the risk of cancer
OCT 14, 2020
Research suggests statins could reduce the risk of cancer
New research published in the journal eLife provides evidence that statins, the common cholesterol-lowering drugs, could ...
NOV 04, 2020
Cancer
Building a New Chemotherapy Drug
NOV 04, 2020
Building a New Chemotherapy Drug
For decades, modern medicine has relied on chemists’ work to produce compounds that could one day be used as a dru ...
Loading Comments...